respiratory
Cystic fibrosis

Ivacaftor ‘window of opportunity’ for CF treatment in children under two


Ivacaftor (Kalydeco) appears safe and effective in treating cycstic fibrosis in children under two and its early use may help preserve pancreatic function, according to results from a phase 3 trial involving two Australian centres. Currently listed on the PBS for CF treatment in children aged two to five, the results from the ARRIVAL trial ...

Already a member?

Enter your email to keep reading.


OR